What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to formally announce and provide investors with Vertex Pharmaceuticals' financial results for the third quarter and the first nine months of 2015. The detailed results are presented in an accompanying press release.

Where can I find the specific financial details for the period?

All the specific financial details, including revenue, expenses, and net income for the three and nine months ended September 30, 2015, are located in the press release dated October 28, 2015, which is attached as Exhibit 99.1 to this 8-K filing.

Are there any significant new business developments or strategic updates mentioned in this filing?

This particular 8-K filing is primarily focused on the release of financial results. It does not appear to contain significant new business developments or strategic updates outside of what would typically be included in a quarterly earnings press release.

What does it mean that the information is 'not deemed to be filed'?

The statement that the information 'shall not be deemed to be 'filed'' means that the content of the press release, while incorporated by reference, is not subject to the liability provisions of Section 18 of the Securities Exchange Act of 1934. This is standard practice for earnings press releases furnished via 8-K.

VRTX 8-K: Earnings & Results

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on October 28, 2015, to report its financial results for the third quarter and the first nine months of 2015, ending September 30, 2015. This filing incorporates by reference a press release dated October 28, 2015, which contains the detailed financial information. Investors should refer to this attached press release for a comprehensive understanding of the company's performance, including revenue, profitability, and any forward-looking statements made by management.

Key Highlights

1Vertex Pharmaceuticals (VRTX) announced its financial results for the three and nine months ended September 30, 2015.
2The 8-K filing incorporates a press release dated October 28, 2015, which contains the detailed financial information.
3Investors are directed to the attached press release (Exhibit 99.1) for specific financial performance data.
4The filing does not contain new operational or strategic disclosures beyond the financial results announcement.
5The information within the press release is furnished, not filed, under Section 18 of the Exchange Act, meaning it does not carry the same liability as formally filed information.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Oct 28, 2015)

Summary

Key Highlights

Frequently Asked Questions